FDA OKs Implant for Diabetic Eye Disease

Ozurdex (dexamethasone) Intravitreal Implant is a steroid injected into the eye to treat swelling that may occur when there is a blockage of certain blood vessels in your eyes, and it is also used to treat non-infectious uveitis affecting the posterior segment of the eye.DME is an eye disease that causes swelling of the retina resulting from leakage of fluids from damaged blood vessels in the eye. It is a major cause of visual loss in diabetics, and is related to poor control of blood glucose.
FDA OKs Implant for Diabetic Eye Disease
By Kristina Fiore, 
The FDA has okayed an intravitreal steroid implant for diabetic macular edema (DME) patients who already have a lens implant or who are going to have cataract surgery.

The 0.7-mg dexamethasone implant (Ozurdex), made by Allergan, comes in a sustained-release biodegradable solid polymer delivery system. The agency approved it today for use in DME patients who have an artificial lens implant (pseudophakic) or who are awaiting surgery (phakic).
The mainstay of DME treatment has been laser photocoagulation of the retina, but the FDA approved a vascular endothelial growth factor (VEGF) inhibitor, ranibizumab (Lucentis), in 2012.
Since the VEGF inhibitor was approved for other eye-related diseases such as age-related macular degeneration (AMD) prior to that time, however, clinicians had been using the less expensive version, bevacizumab (Avastin), off-label for DME…..
More: http://www.medpagetoday.com/Endocrinology/Diabetes/46565
Source: Med Page Today